Romano Quoted in Modern Healthcare About the Need to Change Stark Law and Anti-Kickback Statute Regulations
22 June 2020
Modern Healthcare
Of Counsel Don Romano was quoted in the Modern Healthcare article, “Stark, anti-kickback laws can’t come soon enough, experts say,” which looked at the need for change to Stark Law and Anti-Kickback Statute regulations amid the pandemic. But the pandemic may also delay those rule changes.
COVID-19 could also affect how CMS and OIG finalize the proposed rules because the agencies are considering alternative versions of some proposed policies. “Some of those (policies) may be more liberal than others,” Romano said. “It’s possible that the COVID crisis is going to inform which of those choices the agencies settle on.”
For example, the in-office ancillary services exception is the most important exception under the Stark Law because it requires that a service be performed in a specific place called “the same building” or “centralized building.”
“With the move toward more telehealth … CMS might get to the point where it has a more liberal interpretation of the location requirement, but it can only bend it around the edges because that’s a statutory requirement,” Romano said.
Related News
12 May 2025
In the News
Judith Waltz Comments on Provider Settlement After Self-Disclosure
Foley & Lardner LLP partner Judith Waltz commented on a recent settlement by a provider with the U.S. Department of Health and Human Services Office of Inspector General (OIG) in the Report on Medicare Compliance article, "After Self-Disclosure, Provider Settles Case Over Failure to Report, Return Overpayments."
12 May 2025
In the News
Foley's Digital Infrastructure Arrivals Featured Across Legal Press
Foley & Lardner LLP partners Daniel Farris and Joe McClendon are featured in legal press for their arrival to the firm.
07 May 2025
In the News
Foley Attorneys Featured in Q&A on CPSC Oversight of Cosmetics Industry
Foley & Lardner LLP attorneys Erik Swanholt, Kristin McGaver, and Mikaela Mitchum are featured in a Cosmetics Design Q&A on what industry brands need to know regarding oversight from the U.S. Consumer Product Safety Commission.